The integration of cell therapy with immune checkpoint inhibitors represents a promising advancement in the treatment of hepatocellular carcinoma, particularly with the use of PD-1/PD-L1 inhibitors, which have shown significant effectiveness (173). Here, CD274 is linked to hepatocellular carcinoma.